{"nctId":"NCT04039022","briefTitle":"Open-Label Safety Study of AXS-05 in Subjects With Depression","startDateStruct":{"date":"2019-07-08","type":"ACTUAL"},"conditions":["Major Depressive Disorder","Treatment Resistant Depression","Depression"],"count":876,"armGroups":[{"label":"AXS-05","type":"EXPERIMENTAL","interventionNames":["Drug: AXS-05 (dextromethorphan and bupropion) oral tablets"]}],"interventions":[{"name":"AXS-05 (dextromethorphan and bupropion) oral tablets","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of major depressive disorder, including treatment resistant depression\n* Body mass index (BMI) between 18 and 40 kg/m\\^2, inclusive\n* Agree to use adequate method of contraception for the duration of the study\n* Additional criteria may apply\n\nExclusion Criteria:\n\n* Suicide risk\n* Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study\n* Additional criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of Treatment-emergent AEs (TEAEs) Following Dosing With AXS-05","description":"Types and rates of adverse events","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"505","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":21,"n":876},"commonTop":["Dizziness","Nausea","Headache","Dry mouth","Decreased appetite"]}}}